Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Free Cash Flow (2016 - 2025)

Iovance Biotherapeutics has reported Free Cash Flow over the past 12 years, most recently at -$61.9 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$61.9 million for Q4 2025, up 20.06% from a year ago — trailing twelve months through Dec 2025 was -$336.2 million (up 7.64% YoY), and the annual figure for FY2025 was -$336.2 million, up 7.64%.
  • Free Cash Flow for Q4 2025 was -$61.9 million at Iovance Biotherapeutics, up from -$89.5 million in the prior quarter.
  • Over the last five years, Free Cash Flow for IOVA hit a ceiling of -$61.3 million in Q3 2024 and a floor of -$126.4 million in Q1 2024.
  • Median Free Cash Flow over the past 3 years was -$88.6 million (2023), compared with a mean of -$90.4 million.
  • Biggest five-year swings in Free Cash Flow: surged 30.12% in 2024 and later crashed 46.1% in 2025.
  • Iovance Biotherapeutics' Free Cash Flow stood at -$87.5 million in 2023, then grew by 11.47% to -$77.5 million in 2024, then grew by 20.06% to -$61.9 million in 2025.
  • The last three reported values for Free Cash Flow were -$61.9 million (Q4 2025), -$89.5 million (Q3 2025), and -$74.9 million (Q2 2025) per Business Quant data.